Skip NavigationSkip to Content

The hollow fiber assay: Continued characterization with novel approaches

  1. Author:
    Hall, L. M.
    Krauthauser, C. M.
    Wexler, R. S.
    Hollingshead, M. G.
    Slee, A. M.
    Kerr, J. S.
  2. Author Address

    Hall LM Dupont Merck Pharmaceut Co, Expt Stn E400-5233,Route 141 Henry Clay Rd,POB 80400 Wilmington, DE 19880 USA Dupont Merck Pharmaceut Co, Expt Stn Wilmington, DE 19880 USA NCI, Frederick Canc Res & Dev Ctr, DCTD, Dev Therapeut Program,Biol Testing Branch Frederick, MD 21707 USA
    1. Year: 2000
  1. Journal: Anticancer Research
    1. 20
    2. 2A
    3. Pages: 903-911
  2. Type of Article: Article
  1. Abstract:

    The hollow fiber assay, a unique in vivo model, permits the simultaneous evaluation of compound efficacy against multiple cell lines in two physiological compartments This assay has been used to characterize in vivo activity of cytotoxic compounds. The purpose of the present study was to characterize and optimize this assay for compounds with a defined mechanism of action, specifically cell cycle inhibition. Two human tumor cell lines and one normal human cell line were loaded into polyvinylidene fluoride hollow fibers at two or more cell concentrations and grown in mice for 3-10 days. The data demonstrate the importance of characterizing the initial loading density of various cell lines in the evaluation of compounds. All studies were performed with cells in the linear part of the cell growth curves. Initial loading densities of 1-2 x 10(4) cells/fiber gave the greatest opportunity for growth in the three human cell lines tested (HCT116 colon carcinoma, NCI-H460 non-small cell carcinoma, and AG 1523 normal fibroblast). Utilizing the MTT assay, standard curves were constructed to correlate the fnal number of cells with optical density (OD) readings at 540nm in. order to calculate cell numbers in the fibers. Insights into the mechanism of action of cisplatin have been gained using Western blot analysis of the cell cycle markers PCNA (a protein present throughout the cell cycle) and Rb (a protein that acts as a tumor suppressor gene product) from the hollow fiber cells. In cisplatin-treated NCI-H460 cells both PCNA and Rb phosphorylation decreased, suggesting the arrest of the cells prior to the S phase. Standard therapeutic agents, cisplatin, racemic flavopiridol, cyclophosphamide and mitomycin C, were evaluated independently in the hollow fiber assay and the xenograft model. The data demonstrate that compounds active in the hollow fiber assay are also active in the xenograft. [References: 13]

    See More

External Sources

  1. No sources found.

Library Notes

  1. No notes added.
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel